Vitamin D levels and risk of multiple sclerosis in patients with clinically isolated syndromes

Multiple Sclerosis

Volumn 20, Issue 2, 2014, Pages 147-155

  Martinelli, Vittorio ^a   Dalla Costa, Gloria ^a   Colombo, Bruno ^a   Dalla Libera, Dacia ^a   Rubinacci, Alessandro ^a   Filippi, Massimo ^a   Furlan, Roberto ^a   Comi, Giancarlo ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Multiple sclerosis; natural history studies; risk factors in epidemiology; vitamin D

Indexed keywords

25 HYDROXYVITAMIN D;

ADULT; ARTICLE; CEREBROSPINAL FLUID; DEMYELINATING DISEASE; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; RISK FACTOR; SEX DIFFERENCE; VITAMIN BLOOD LEVEL; YOUNG ADULT; AGE DISTRIBUTION; CEREBROSPINAL FLUID ANALYSIS; CLINICALLY DEFINITE MULTIPLE SCLEROSIS; CONTROLLED STUDY; HIGH RISK POPULATION; NEUROIMAGING; RETROSPECTIVE STUDY; RISK ASSESSMENT; VITAMIN D DEFICIENCY;

MULTIPLE SCLEROSIS; NATURAL HISTORY STUDIES; RISK FACTORS IN EPIDEMIOLOGY; VITAMIN D;

ADOLESCENT; ADULT; DEMYELINATING DISEASES; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; RETROSPECTIVE STUDIES; RISK FACTORS; VITAMIN D; VITAMIN D DEFICIENCY; VITAMINS; YOUNG ADULT;

EID: 84893635002     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458513494959     Document Type: Article

References (35)

1. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors. Ann Neurol. 2007 ; 61: 504-513
2. Oksenberg JR, Baranzini SE, Sawcer S, et al. The genetics of multiple sclerosis: SNPs to pathways to pathogenesis. Nat Rev Genet. 2008 ; 9: 516-526
3. Ebers GC, Bulman DE, Sadovnick AD, et al. A population-based study of multiple sclerosis in twins. N Engl J Med. 1986 ; 315: 1638-1642
4. Elian M, Nightingale S, Dean G. Multiple sclerosis among United Kingdom-born children of immigrants from the Indian subcontinent, Africa and the West Indies. J Neurol Neurosurg Psychiatry. 1990 ; 53: 906-911
5. Kahana E, Zilber N, Abramson JH, et al. Multiple sclerosis: Genetic versus environmental aetiology: Epidemiology in Israel updated. J Neurol. 1994 ; 241: 341-346
6. Lyakh LA, Sanford M, Chekol S, et al. TGF- and vitamin D3 utilize distinct pathways to suppress IL-12 production and modulate rapid differentiation of human monocytes into CD83 dendritic cells. J Immunol. 2005 ; 174: 2061-2070
7. Chen S, Sims GP, Chen XX, et al. Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol. 2007 ; 179: 1634-1647
8. Spach KM, Nashold FE, Dittel BN, et al. IL-10 signaling is essential for 1,25-dihydroxyvitamin D3-mediated inhibition of experimental autoimmune encephalomyelitis. J Immunol. 2006 ; 177: 6030-6037
9. Nashold FE, Hoag KA, Goverman J, et al. Rag-1-dependent cells are necessary for 1,25-dihydroxyvitamin D(3) prevention of experimental autoimmune encephalomyelitis. J Neuroimmunol. 2001 ; 119: 16-29
10. Barrat FJ, Cua DJ, Boonstra A, et al. In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J Exp Med. 2002 ; 195: 603-616
11. Spach KM, Pedersen LB, Nashold FE, et al. Gene expression analysis suggests that 1,25-dihydroxyvitamin D3 reverses experimental autoimmune encephalomyelitis by stimulating inflammatory cell apoptosis. Physiol Genomics. 2004 ; 18: 141-151
12. Pedersen LB, Nashold FE, Spach KM, et al. 1,25-dihydroxyvitamin D3 reverses experimental autoimmune encephalomyelitis by inhibiting chemokine synthesis and monocyte trafficking. J Neurosci Res. 2007 ; 85: 2480-2490
13. Munger KL, Levin LI, Hollis BW, et al. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA. 2006 ; 296: 2832-2838
14. Hiremath GS, Cettomai D, Baynes M, et al. Vitamin D status and effect of low-dose cholecalciferol and high-dose ergocalciferol supplementation in multiple sclerosis. Mult Scler. 2009 ; 15: 735-740
15. Pierrot-Deseilligny C. Clinical implications of a possible role of vitamin D in multiple sclerosis. J Neurol. 2009 ; 256: 1468-1479
16. van der Mei IA, Ponsonby AL, Dwyer T, et al. Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. J Neurol. 2007 ; 254: 581-590
17. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: Guidelines for research proposals. Ann Neurol. 1983 ; 13: 227-231
18. Agborsangaya C, Toriola AT, Grankvist K, et al. The effect of storage time and sampling season on the stability of serum 25-hydroxy vitamin D and androstenedione. Nutr Cancer. 2010 ; 62: 51-57
19. Bliss CI. Periodic regression in biology and climatology. Conn Agr Exp St. 1958 ; 615: 3-55
20. Heinzl H, Kaider A. Gaining more flexibility in Cox proportional hazards regression models with cubic spline functions. Comput Methods Programs Biomed. 1997 ; 54: 201-208
21. Harrell FE General aspects of fitting regression models: Regression modeling strategies. New York, NY: Springer Science+Business Media Inc ; 2001: 23.
22. Adami S, Bertoldo F, Braga V, et al. 25-hydroxyvitamin D levels in healthy premenopausal women: Association with bone turnover markers and bone mineral density. Bone. 2009 ; 45: 423-426
23. Dietary reference intakes for calcium and vitamin D. Washington, DC: The National Academies Press ; 2010:
24. Overbergh L, Decallonne B, Valckx D, et al. Identification and immune regulation of 25-hydroxyvitamin D-1-alpha-hydroxylase in murine macrophages. Clin Exp Immunol. 2000 ; 120: 139-146
25. Munger KL, Zhang SM, O'Reilly E, et al. Vitamin D intake and incidence of multiple sclerosis. Neurology. 2004 ; 62: 60-65
26. Soilu-Hänninen M, Airas L, Mononen I, et al. 25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis. Mult Scler. 2005 ; 1: 266-271
27. Mowry E, Krupp L, Milazzo M, et al. Vitamin D status is associated with relapse rate in pediatric-onset MS. Ann Neurol. 2010 ; 67: 618-624
28. Ascherio A, Munger K, Simon C, et al. Serum 25-hydroxyvitamin D concentrations among patients in BENEFIT predicts conversion to multiple sclerosis, MRI lesions, and brain volume loss. Mult Scler. 2012b ; 18: 374-375
29. IARC Working Group Reports. Lyon, France: International Agency for Research on Cancer ; 2008 2008: 2.
30. Pierrot-Deseilligny C, Rivaud-Péchoux S, Clerson P, et al. Relationship between 25-OH-D serum level and relapse rate in multiple sclerosis patients before and after vitamin D supplementation. Ther Adv Neurol Disord. 2012 ; 5: 187-198
31. Nashold FE, Spach KM, Spanier JA, et al. Estrogen controls vitamin D3-mediated resistance to experimental autoimmune encephalomyelitis by controlling vitamin D3 metabolism and receptor expression. J Immunol. 2009 ; 183: 3672-3681
32. Koch-Henriksen N, Sørensen PS. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol. 2010 ; 9: 520-532
33. Spach KM, Hayes CE. Vitamin D3 confers protection from autoimmune encephalomyelitis only in female mice. J Immunol ; 2005 ; 2005. 4119.
34. Steyerberg E Clinical prediction models. Gail M Tsiatis A Krickeberg K, ed. New York, NY: Springer ; 2009: 159-173.
35. Platz EA, Leitzmann MF, Hollis BW, et al. Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer. Cancer Causes Control. 2004 ; 15: 255-265